/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
All currency values in $ millions unless otherwise noted
Scroll
| Income Statement | SEP 2025 | SEP 2024 | SEP 2023 | SEP 2022 | SEP 2021 |
|---|---|---|---|---|---|
| General & Administrative | $14 | $11 | $12 | $13 | $9 |
| Research & Development | $38 | $42 | $44 | $38 | $33 |
| Total Operating Expenses | $51 | $53 | $56 | $51 | $42 |
| Operating Income | -$51 | -$53 | -$56 | -$51 | -$42 |
| Other Non-Operating Income (Expense) | $5 | $10 | $8 | $2 | $4 |
| EBT (Earnings Before Tax) | -$46 | -$43 | -$47 | -$48 | -$38 |
| Net Income | |||||
| Net Income | -$46 | -$43 | -$48 | -$48 | -$38 |
| EPS (Basic) | -$0.54 | -$0.52 | -$0.60 | -$0.62 | -$0.54 |
| EPS (Diluted) | -$0.54 | -$0.52 | -$0.60 | -$0.62 | -$0.54 |
| Weighted Avg Shares (Basic) | 85.3M | 83.5M | 79.8M | 76.9M | 69.8M |
| Weighted Avg Shares (Diluted) | 85.3M | 83.5M | 79.8M | 76.9M | 69.8M |
| Shares Outstanding | 85.3M | 83.5M | 79.8M | 76.9M | 69.8M |
Anavex Life Sciences (AVXL) generated about n/a in revenue and -$13 million in net income over the trailing twelve months. Figures are from SEC filings; this is analysis, not investment advice.
Anavex Life Sciences reported about -$13 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.
SourceFinancial statements computed from the 10-Q filed 28 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 29 Aug 2026. How this is calculated.
Fiscal year ends Sep.